PTC Therapeutics
PTCTPTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.In September 2009, PTC entered into an agreement with R …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2024-2026
All insider trades at PTC Therapeutics
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 4/6/2026 | Sell | Boulding, Mark Elliott | EXEC. VP AND CLO | $69.3 | $157,293 |
| 4/2/2026 | Sell | Golden, Lee Scott | EVP & CHIEF MEDICAL OFFICER | $68.0 | $56,364 |
| 4/1/2026 | Sell | Almstead, Neil Gregory | CHIEF TECHNICAL OPS OFFICER | $69.6 | $3,590,243 |
| 3/12/2026 | Sell | Klein, Matthew B. | CHIEF EXECUTIVE OFFICER | $64.1 | $170,581 |
| 3/10/2026 | Sell | Okey, Stephanie | Director | $70.0 | $1,061,690 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)